@article {7678,
	title = {Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents},
	journal = {International Journal of Cancer},
	volume = {130},
	year = {2012},
	note = {Cited By :13Export Date: 21 February 2017},
	month = {2012},
	pages = {735 - 742},
	abstract = {The circulating levels of several angiogenic cytokines [angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), angiogenin and basic fibroblast growth factor (bFGF)] were evaluated in 174 consecutive patients with newly diagnosed, symptomatic, multiple myeloma (MM). Circulating levels of Ang-1/Ang-2 were reduced in myeloma patients compared to controls, whereas VEGF and angiogenin levels were increased. Reduced angiopoietin-1/angiopoietin-2 ratio correlated with advanced disease features including international staging system (ISS)-3 stage, renal impairment and extensive bone disease. Based on immunohistochemical results in 20 patients (10 with the higher and 10 with the lower values of circulating angiopoietin-2) we found that angiopoietin-2 is expressed by myeloma cells and correlates with increased microvessel density in subsets of patients. Furthermore, Ang-1/Ang-2 ratio correlated with survival. Patients with circulating Ang-1/Ang-2 below or equal to the median value (6.03) had a median survival of 26.3 months compared to 53 months of all others (p = 0.002). Interestingly, this was mainly observed in patients who received first-line therapy with novel agent-based regimens (65\% of our patients). Furthermore, a subset of ISS-3 patients with serum Ang-1/Ang-2 above the median value had favourable prognosis (median survival: 45 months versus 17 months of all others; p = 0.0001). The multivariate analysis revealed that low Ang-1/Ang-2 ratio could independently predict for inferior survival in our cohort of patients (relative risk (RR) 2.07, 95\% CI 1.50-2.42; p < 0.001). These results highlight the role of angiopoietins pathway in the biology of MM and reveal novel targets for the development of antimyeloma agents. Copyright {\textcopyright} 2011 UICC.},
	keywords = {Angiogenesis, angiopoietin-1, angiopoietin-2, multiple myeloma, Survival},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-82255191895\&doi=10.1002\%2fijc.26062\&partnerID=40\&md5=5d33d8e5c89e9314effb8d7bac6daf5c},
	author = {Terpos, E. and Anargyrou, K. and Katodritou, E. and Kastritis, E. and Papatheodorou, A. and Christoulas, D. and Pouli, A. and Michalis, E. and Delimpasi, S. and Gkotzamanidou, M. and Nikitas, N. and Koumoustiotis, V. and Margaritis, D. and Tsionos, K. and Stefanoudaki, E. and Meletis, J. and Zervas, K. and Dimopoulos, M.A.}
}
